sam-altman
(2)
Retro Biosciences
Retro Biosciences is a clinical-stage longevity biotech in Redwood City, California with a single, unsubtle goal: add ten healthy years to the human lifespan. Founded in 2018 and launched publicly in 2021 with $180 million from OpenAI CEO Sam Altman, the company attacks aging at the cellular level across three platforms - autophagy enhancement, cellular reprogramming, and plasma-inspired therapeutics. Its lead drug, RTR242, an autophagy-restoring small molecule aimed at Alzheimer's disease, entered a first-in-human Phase 1 trial in 2025. A 2026 raise valued Retro at $1.8 billion.
World
World (formerly Worldcoin) is building a global "proof of human" network for the AI age. Created by Tools for Humanity and co-founded by OpenAI's Sam Altman and CEO Alex Blania, World lets people prove they are a real, unique human online without revealing who they are. Users verify with the Orb, a custom iris-scanning device, and receive a private World ID plus access to the World App, World Chain (an Ethereum Layer 2), and the WLD token. The pitch is simple: as AI makes bots indistinguishable from people, the internet needs a privacy-preserving way to tell humans apart from machines.